| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
MUC1 Blocking Peptide for STJ501818 is synthetically produced from the sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Dilution Range: |
WB: IHC: 1:200ICC: 1:200IF: 1:200CFM: 1:200 |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
MUC1 |
| Gene ID: |
4582 |
| Uniprot ID: |
MUC1_HUMAN |
| Specificity: |
This blocking peptide is recommended for use in combination with MUC1 antibody, STJ501818 |
| Immunogen: |
Synthetic peptide corresponding to unique amino acid sequence on MUCIN1 protein. |
| Tissue Specificity | Expressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform Y is expressed in tumor cells only. |
| Post Translational Modifications | Highly glycosylated (N- and O-linked carbohydrates and sialic acid). O-glycosylated to a varying degree on serine and threonine residues within each tandem repeat, ranging from mono- to penta-glycosylation. The average density ranges from about 50% in human milk to over 90% in T47D breast cancer cells. Further sialylation occurs during recycling. Membrane-shed glycoproteins from kidney and breast cancer cells have preferentially sialyated core 1 structures, while secreted forms from the same tissues display mainly core 2 structures. The O-glycosylated content is overlapping in both these tissues with terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6-linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O-glycosylated in breast carcinomas with 3,4-linked GlcNAc. N-glycosylation consists of high-mannose, acidic complex-type and hybrid glycans in the secreted form MUC1/SEC, and neutral complex-type in the transmembrane form, MUC1/TM. Proteolytic cleavage in the SEA domain occurs in the endoplasmic reticulum by an autoproteolytic mechanism and requires the full-length SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 site. Cleavage at this site also occurs on isoform MUC1/X but not on isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17. Dual palmitoylation on cysteine residues in the CQC motif is required for recycling from endosomes back to the plasma membrane. Phosphorylated on tyrosines and serine residues in the C-terminal. Phosphorylation on tyrosines in the C-terminal increases the nuclear location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3B-mediated phosphorylation on Ser-1227 decreases this interaction but restores the formation of the beta-cadherin/E-cadherin complex. On T-cell receptor activation, phosphorylated by LCK. PDGFR-mediated phosphorylation increases nuclear colocalization of MUC1CT and CTNNB1. The N-terminal sequence has been shown to begin at position 24 or 28. |
| Function | The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack. The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity. |
| Peptide Name | Mucin-1Muc-1Breast Carcinoma-Associated Antigen Df3Cancer Antigen 15-3Ca 15-3Carcinoma-Associated MucinEpisialinH23agKrebs Von Den Lungen-6Kl-6PemtPeanut-Reactive Urinary MucinPumPolymorphic Epithelial MucinPemTumor-Associated Epithelial Membrane AntigenEmaTumor-Associated MucinCd Antigen Cd227 Cleaved Into - Mucin-1 Subunit AlphaMuc1-NtMuc1-Alpha - Mucin-1 Subunit BetaMuc1-BetaMuc1-Ct |
| Database Links | Reactome: R-HSA-5083625Reactome: R-HSA-5083632Reactome: R-HSA-5083636Reactome: R-HSA-5621480Reactome: R-HSA-6785807Reactome: R-HSA-913709Reactome: R-HSA-977068 |
| Cellular Localisation | Apical Cell MembraneSingle-Pass Type I Membrane ProteinExclusively Located In The Apical Domain Of The Plasma Membrane Of Highly Polarized Epithelial CellsAfter EndocytosisInternalized And Recycled To The Cell MembraneLocated To Microvilli And To The Tips Of Long Filopodial ProtusionsIsoform 5: SecretedIsoform Y: SecretedIsoform 9: SecretedMucin-1 Subunit Beta: Cell MembraneCytoplasmNucleusOn Egf And Pdgfrb StimulationTransported To The Nucleus Through Interaction With Ctnnb1A Process Which Is Stimulated By PhosphorylationOn Hrg StimulationColocalizes With Jup/Gamma-Catenin At The Nucleus |
| Alternative Peptide Names | Mucin-1 proteinMuc-1 proteinBreast Carcinoma-Associated Antigen Df3 proteinCancer Antigen 15-3 proteinCa 15-3 proteinCarcinoma-Associated Mucin proteinEpisialin proteinH23ag proteinKrebs Von Den Lungen-6 proteinKl-6 proteinPemt proteinPeanut-Reactive Urinary Mucin proteinPum proteinPolymorphic Epithelial Mucin proteinPem proteinTumor-Associated Epithelial Membrane Antigen proteinEma proteinTumor-Associated Mucin proteinCd Antigen Cd227 Cleaved Into - Mucin-1 Subunit Alpha proteinMuc1-Nt proteinMuc1-Alpha - Mucin-1 Subunit Beta proteinMuc1-Beta proteinMuc1-Ct proteinMUC1 proteinPUM protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
